‘Winner Antibody’ holds promise as universal Influenza A Vaccine

21/07/2016 - 3 minutes

MedImmune and Humabs have reasons to be happy. Their candidate for an Influenza A vaccine has made it into well-known journal, Cell, boasting a unique affinity to the virus with multiple mechanisms to stop infection.

medimmune antibody influenza a vaccineThe promising candidate is MEDI8852, an antibody initially developed by Humabs (Switzerland). It targets Influenza A virus (the group of viruses known as avian flu), which is responsible for most influenza hospitalizations and has had health authorities concerned about a possible pandemic.

MEDI8852 was the result of Humab’s platform to use human memory B-cells from patients that recovered from infectious diseases and isolate their ‘winner antibodies’. Besides Influenza, this strategy also yielded results against cytomegalovirus, Middle East Respiratory Syndrome (MERS) and Ebola.

The antibody was later picked up by MedImmune, which is now conducting  Phase Ib/IIa trials. The results so far had already earned it a Fast Track designation from the FDA.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member